Astellas signs AI Proteins miniprotein discovery deal worth more than $400m

Astellas Pharma has signed a drug discovery agreement with AI Proteins, a Boston company that designs miniproteins computationally, in a deal that milestones could take above $400 million. The companies announced it on 21 October 2026¹.

The terms

AI Proteins receives an upfront fee that neither side has disclosed, with milestone payments making up the rest of the headline value. Astellas takes on development, regulatory work and commercialisation of any assets that come out of the collaboration¹. Neither the targets nor the therapeutic areas have been named, and the deal is described as fitting Astellas' agnostic stance on disease areas and modalities¹.

The platform builds miniproteins from scratch rather than starting from a natural molecule. AI Proteins says its designs have shown binding activity "beyond what's possible with traditional nature-derived biologics"¹. Chris Bahl, the company's founder and chief executive, said the approach lets it "specify what a medicine needs to do, then build a molecule from scratch to do precisely that"¹.

What it means for the market

The deal is the second of this size for AI Proteins. It signed a $400 million agreement with Bristol Myers Squibb at the end of 2024, and an R&D collaboration with Vivtex, an oral biologics company, earlier that year¹. For a company whose last equity round was a $41.5 million Series A in November 2025, after an $18.2 million seed in 2022, repeat big pharma partnerships are the main route to validating the platform and funding it without heavy dilution¹.

For Astellas, the agreement is a bet on early-stage research rather than late-stage acquisitions. The company faces a patent cliff on Xtandi, its cancer drug, which brought in $6 billion in sales last year¹. Naoki Okamura, the chief executive, said in January that Astellas would rather "invest in [the] much longer term" than patch the gap through conventional business development¹. Morten Sogaard, senior vice president of Astellas Innovation Lab, said the partnership reflects a focus on "strengthening our early-stage research pipeline"¹.

Astellas has been using AI in its own development work since 2019, through what it calls a "human-in-the-loop" platform for data collection and research¹. Folding in AI Proteins' platform is meant to widen its early-stage pipeline¹.

Most of the headline value sits in milestones, with only an undisclosed fee paid at signing¹. The $400 million figure is therefore a ceiling rather than committed cash. The size of the upfront payment, the clearest sign of how much Astellas is putting in now, has not been made public¹.

Caveats

The sole source is a trade press report built on the companies' release, and it gives no programme count, timelines or upfront figure¹. The deal covers discovery only. Astellas will lead any later development and commercialisation, so any revenue for AI Proteins beyond milestones will depend on Astellas advancing candidates through trials¹.